Patents by Inventor Dharmarao Thapi

Dharmarao Thapi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TO GALECTIN-3 AND METHODS OF USE THEREOF
    Publication number: 20240026009
    Abstract: Provided herein are compositions, methods, and uses involving antibodies that specifically bind the Galectin-3 (LGALS3) carbohydrate binding domain (CBD). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.
    Type: Application
    Filed: December 7, 2021
    Publication date: January 25, 2024
    Inventors: David SPRIGGS, Dharmarao THAPI, Ivo C. LORENZ, Thomas E. WHITE
  • Antibodies to MUC16 and methods of use thereof
    Patent number: 11834513
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: December 5, 2023
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: David Spriggs, Dharmarao Thapi
  • ANTI-MUC16 ANTIBODIES AND USES THEREOF
    Publication number: 20230026100
    Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.
    Type: Application
    Filed: July 14, 2021
    Publication date: January 26, 2023
    Inventors: David SPRIGGS, Alberto FERNANDEZ-TEJADA, Dharmarao THAPI
  • HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
    Publication number: 20220235143
    Abstract: Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.
    Type: Application
    Filed: May 7, 2020
    Publication date: July 28, 2022
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: David SPRIGGS, Dharmarao THAPI, Su YAN, Cheng LIU
  • ANTIBODIES TO MUC16 AND METHODS OF USE THEREOF
    Publication number: 20210309758
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.
    Type: Application
    Filed: July 28, 2020
    Publication date: October 7, 2021
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: David Spriggs, Dharmarao Thapi
  • Anti-MUC16 antibodies and uses thereof
    Patent number: 11066480
    Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: July 20, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Spriggs, Alberto Fernandez-Tejada, Dharmarao Thapi
  • ANTIBODIES TO GALECTIN-3 AND METHODS OF USE THEREOF
    Publication number: 20210032350
    Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind the Galactin-3 (LGALS3) carbohydrate binding domain (CBD). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.
    Type: Application
    Filed: February 1, 2019
    Publication date: February 4, 2021
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David SPRIGGS, Dharmarao THAPI, Marina STASENKO
  • Antibodies to MUC16 and methods of use thereof
    Patent number: 10759869
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: September 1, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: David Spriggs, Dharmarao Thapi
  • ANTIBODIES TO MUC16 AND METHODS OF USE THEREOF
    Publication number: 20180230231
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.
    Type: Application
    Filed: September 5, 2017
    Publication date: August 16, 2018
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: David Spriggs, Dharmarao Thapi
  • ANTI-MUC16 ANTIBODIES AND USES THEREOF
    Publication number: 20180112008
    Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.
    Type: Application
    Filed: March 16, 2016
    Publication date: April 26, 2018
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: David SPRIGGS, Alberto FERNANDEZ-TEJADA, Dharmarao THAPI
  • Antibodies to MUC16 and methods of use thereof
    Patent number: 9790283
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: October 17, 2017
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: David Spriggs, Dharmarao Thapi
  • ANTIBODIES TO MUC16 AND METHODS OF USE THEREOF
    Publication number: 20160168262
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.
    Type: Application
    Filed: September 10, 2015
    Publication date: June 16, 2016
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: David Spriggs, Dharmarao Thapi
  • Antibodies to MUC16 and methods of use thereof
    Patent number: 9169328
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: October 27, 2015
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: David Spriggs, Dharmarao Thapi
  • ANTIBODIES TO MUC16 AND METHODS OF USE THEREOF
    Publication number: 20130171152
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.
    Type: Application
    Filed: March 25, 2011
    Publication date: July 4, 2013
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: David Spriggs, Dharmarao Thapi